Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity

v3.22.4
Stockholders’ Equity
 3 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Stockholders’ Equity

6. Stockholders’ Equity

 

During the three months ended December 31, 2022, the Company sold an aggregate of 2,416,487 shares of common stock pursuant to the 2022 Sales Agreement with BTIG for gross proceeds of $4.8 million and net proceeds of $4.5 million.

 

Common stock warrants

 

As of December 31, 2022, the following equity-classified warrants and related terms were outstanding:

 

   

Warrants

Outstanding

     Exercise Price     Expiration Date
Common stock warrants     2,827,708     $ 11.90     August 24, 2026
Underwriter warrants     50,416     $ 14.875     August 19, 2026
Private warrants     2,059     $ 410.48     January 6, 2023 - March 10, 2023
Chanticleer warrants     1,267     $ 819.00 - $1,274.00     April 30, 2027 - December 17, 2028
Series C warrants     809,243     $ 44.66     October 16, 2025
Series 3 warrants     276,140     $ 4.074     August 15, 2027
      3,966,833              

 

During the three months ended December 31, 2022, 3,026 of Series B warrants were net share settled, resulting in the issuance of 3,026 shares of common stock.

 

 

Sonnet BioTherapeutics Holdings, Inc.

Notes to Unaudited Interim Consolidated Financial Statements